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Receipt of fluoroquinolones was the predominant risk
factor for Clostridium difficile–associated disease (CDAD)
during an epidemic in Quebec, Canada. To determine the
role of antimicrobial drugs in facilitating healthcare-associ-
ated methicillin-resistant Staphylococcus aureus (MRSA)
colonization and infection and to compare this role with
their effects on methicillin-susceptible S. aureus infection
and CDAD, we conducted a retrospective cohort study of
patients in a Quebec hospital. For 7,371 episodes of care,
data were collected on risk factors, including receipt of
antimicrobial drugs. Crude and adjusted hazard ratios
(AHR) were calculated by Cox regression. Of 150 episodes
of MRSA colonization and 23 of MRSA infection, fluoro-
quinolones were the only antimicrobials that increased risk
for colonization (AHR 2.57, 95% confidence interval [CI]
1.84–3.60) and infection (AHR 2.49, 95% CI 1.02–6.07).
Effect of antimicrobial drugs on MRSA colonization and
infection was similar to effect on CDAD and should be con-
sidered when selecting antimicrobial drugs to treat com-
mon infections.
S
taphylococcus aureus remains an important nosocomi-
al pathogen because of its virulence and adapting
resistance mechanisms (1–3). Methicillin-resistant S.
aureus (MRSA) has become widespread in hospitals
worldwide and is now causing outbreaks in communities
as well (2,4–6). In the United States, almost two thirds of
S. aureus isolates from patients in intensive care units are
methicillin resistant (6). In Canada, MRSA prevalence
varies geographically and is highest in Quebec (27%) (7).
In the Centre Universitaire Hospitalier de Sherbrooke,
prevalence of MRSA increased from 5% of isolates in
2001 to 16% in 2004. Risk factors for infection by methi-
cillin-sensitive S. aureus (MSSA) and MRSA include hos-
pitalization, longer stay in a hospital, stay in an intensive
care unit (ICU), more concurrent illnesses, residence in a
long-term care facility, catheterization (central access or
other venous), diabetes mellitus, cancer, surgery, wounds,
hemodialysis, and HIV infection (1,8–16). Antimicrobial
drugs, especially β-lactams, fluoroquinolones, and
macrolides, have been incriminated as potentially facilitat-
ing MSSA and MRSA infections (9,15–19), but this asso-
ciation remains controversial. During a large epidemic of
Clostridium difficile–associated disease (CDAD) in the
province of Quebec, receipt of fluoroquinolones emerged
as the predominant risk factor for CDAD in a large cohort
study of inpatients at the Centre Universitaire Hospitalier
de Sherbrooke, a 683-bed tertiary-care hospital (20). The
commonality of risk factors for CDAD and MRSA has
been noted before (15). To determine the role of various
antimicrobial drugs in favoring healthcare-associated
MRSA colonization and infection, we examined the same
cohort of patients to identify risk factors for these out-
comes and for MSSA infection.
Methods
Records of all adult patients hospitalized at least once
from January 2003 through June 2004 in 3 wards (internal
medicine, family medicine, gastroenterology) and a ran-
dom sample of 50% of patients in the general surgery ward
were retrospectively reviewed (20). For each patient,
records of all admissions during this period were exam-
ined. To deal with multiple hospitalizations and repeated
exposures, we used episodes of care (EOC) as the unit for
all analyses (20). When intervals between hospital admis-
sions were ≤60 days, distinct hospitalizations were consid-
ered as a single EOC and duration of stay was the sum of
each admission within that EOC. Hospitalizations >60
days apart were defined as separate EOCs. We excluded
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sion was S. aureus infection or during which S. aureus
infection was documented within 72 hours of admission.
The following data were collected for each patient:
sociodemographic information, discharge diagnoses and
concurrent illnesses, pharmaceutical drugs given, and lab-
oratory test results. Receipt of antimicrobial drugs while in
the hospital was abstracted from computerized medical
records. When possible, receipt of antimicrobial drugs as
outpatient therapy in the 2 months before the EOC was
abstracted from the admission note. The overall amount of
concurrent illness was measured according to the Charlson
index (21). Apatient with any of the following was consid-
ered immunosuppressed: HIV infection, leukemia, lym-
phoma, neutropenia, organ transplant, or other indications
for receiving immunosuppressive drugs or systemic corti-
costeroids for ≥1 month. Potential outcomes were identi-
fied through a review of a laboratory database of clinical
specimens (infections with MSSA or MRSA) and of the
hospital’s computerized database (MRSA colonization).
When MRSA infection or colonization or MSSA infection
developed, data with regard to risk factors were collected
from date of first admission up to the date of microbiolog-
ic and clinical diagnosis. A case of nosocomial MRSA or
MSSAinfection was defined by 1) a positive S. aureus cul-
ture from a site considered infected by the treating physi-
cians and for which antimicrobial drug therapy active
against the pathogen was initiated or surgical drainage was
performed and 2) occurrence of the above during an EOC
or within 60 days of date of last discharge after an EOC.
Patients were considered to have MRSA colonization if
MRSAwas recovered in a surveillance sample or in a clin-
ical sample and the patient had not received vancomycin,
linezolid, or cotrimoxazole. Patients for whom MSSA was
found in a specimen but for whom no antistaphylococcal
drug had been prescribed and for whom no surgical
drainage had been performed were considered to have
MSSA colonization and were not analyzed further.
During the study period, hospital policy was to screen
all new patients who had been hospitalized during the pre-
vious year for MRSA colonization, by swabbing anterior
nares, perineum, and dermal lesions (if any). Screening
was thereafter repeated if the patient had contact with
another patient who had MRSAor was transferred to ICU.
Weekly screening for 4 consecutive weeks after an out-
break was also performed for patients in involved wards.
Barrier precautions were initiated for all patients with
MRSA colonization or infection. For the analysis of
MRSA colonization, we excluded patients colonized with
MRSA at the time of admission and patients who had no
follow-up swabs taken to detect MRSA colonization after
admission. A patient who satisfied the following criteria
was considered to have acquired MRSA colonization: 1)
no evidence of colonization at the time of admission
(screening with negative results or no screening), 2) a pos-
itive result for MRSAduring a follow-up screening, and 3)
no evidence of active infection as defined by the adminis-
tration of a drug active against MRSAor surgical drainage.
Crude and adjusted hazard ratios (AHR) were meas-
ured by using Cox regression analysis. Day 0 correspond-
ed to the date of first admission in an EOC. Data were
censored when the patient died or when 60 days had
passed since the date of last discharge within that EOC,
whichever came first. Variables significantly associated
with the outcome in univariate analyses were tested in Cox
multivariate models built up sequentially, starting with the
variable most strongly associated with the outcome and
continuing until no other variable reached significance.
When the final model was reached, each variable was
dropped in turn to assess its effect by using the likelihood
ratio test. We kept in the final models variables that signif-
icantly enhanced the fit at the p≤0.05 level. Interactions
were sought between variables that were independently
associated with the outcomes. The proportional hazards
assumption was verified by comparing the Kaplan-Meier
curve to the Cox predicted curve for a given variable and
by assessing the parallel nature of curves in log-log plots.
Until April 2003, clinical specimens and swabs for
MRSA detection were put on plates of blood agar and
mannitol salt agar, and S. aureus was confirmed by bound-
coagulase test (Pasteurex, Sanofi Diagnostics Pasteur Ltd.,
Surrey, UK). Isolates found to be oxacillin resistant (<10
mm) or to have intermediate resistance to oxacillin (11–12
mm) on a Kirby-Bauer disk diffusion assay were further
tested by Etest on Mueller-Hinton agar with 2% sodium
chloride incubated for 24 hours at 37°C. Those with a MIC
≥4 µmol/mL were considered to be MRSA. Since April
2003, MRSA has been confirmed by identifying the mecA
gene by using PCR (LightCycler, Roche, Mannheim,
Germany) in addition to oxacillin Etest.
Results
Patient Characteristics
Of 7,421 EOCs in the original cohort (20), 50 were
excluded because a staphylococcal infection was the pri-
mary reason for admission or was documented within 72
hours of admission, which left 7,371 EOCs for the analy-
sis of MRSA and MSSA infections. Of these patients,
3,432 (47%) were male, median age was 72 years, only
one fifth (21%) had no concurrent illness (Charlson score
0), 21% stayed in ICU, and 20% had surgery. Almost half
(46%) received antimicrobial drugs, most commonly fluo-
roquinolones (22.9%), second-generation cephalosporins
(13.6%), metronidazole (9.1%), and first- (8.5%) and
third-generation cephalosporins (7.7%). A nosocomial
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tract, 6 surgical wound, 4 urinary tract, 2 endovascular, 2
osteomyelitis, and 1 mediastinitis), and a nosocomial
MSSA infection developed in 66 (15 respiratory tract, 15
soft tissue, 14 surgical wound, 7 endovascular, 7 urinary
tract, 5 osteomyelitis, 3 mediastinitis).
MRSA Colonization
For the analysis of risk factors for MRSA colonization,
2,767 EOCs were retained. The others were excluded
because of colonization at time of admission (n = 84) or
because no follow-up screening for MRSA was performed
(n = 4,520). The proportion of patients who had >1 follow-
up screening assay for MRSA colonization increased from
5.7% of those hospitalized for 1 to 3 days to 74.2% of
patients hospitalized for >15 days. Compared with the
larger cohort described above, patients in this smaller
cohort were older (median age 75 years), more likely to
have concurrent illness (12%), more likely to have stayed
in ICU (31%), more likely to have had surgery (25%), and
more likely to have received antimicrobial drugs (57%),
specifically fluoroquinolones (31.4%), second-generation
cephalosporins (17.6%), metronidazole (13.6%), first-gen-
eration cephalosporins (13.0%), and third-generation
cephalosporins (10.8%).
MRSA colonization developed in 150 patients. After
confounding variables were adjusted for, the independent
risk factors were age, duration of hospitalization, peptic
ulcer disease, and receipt of fluoroquinolones. Receipt of
narrow-spectrum penicillins had a protective effect
(Table 1). Sex and an immunosuppressed condition were
not associated with MRSA colonization (data not shown).
Although their 95% confidence intervals (CIs) encom-
passed the null value, the protective effect of cotrimoxa-
zole and the deleterious effect of H2-blockers significantly
enhanced the fit and were retained in the final model. The
association between use of fluoroquinolones and coloniza-
tion with MRSAwas not modified by duration of treatment
(data not shown) but was somewhat stronger for those who
received ciprofloxacin (n = 576, AHR 2.53, 95% CI
1.73–3.69) than those who received levofloxacin (n = 167,
AHR 1.77, 95% CI 0.95–3.28). When both drugs were
given sequentially, the AHR was higher (n = 79, AHR
5.18, 95% CI 2.99–8.96). After adjustment for con-
founders, none of the other antimicrobial drugs was asso-
ciated with MRSA colonization. Receipt of clindamycin
tended to be associated with colonization with MRSA
(AHR 1.87, 95% CI 0.93–3.74, p = 0.08), but it was given
to only 2.6% of patients. No interaction was found.
MRSA Infection
For analysis of MRSA infections, we could use all
7,371 EOCs, but power was limited by the small number
of outcomes (n = 23). MRSAcolonization at time of admis-
sion was by far the strongest independent risk factor for
MRSA infection (Table 2). The other independent risk fac-
tors were having undergone surgery, having received fluo-
roquinolones or systemic corticosteroids, and having a
history of peptic ulcer disease. Sex and immunosuppression
were not associated with MRSAinfection (data not shown).
For the fluoroquinolones (whose median duration of use
was 5 days), AHR was higher for the 958 patients who
received this class of antimicrobial drugs for >5 days (AHR
3.70, 95% CI 1.49–9.18) because MRSA infection did not
develop in any of the 699 patients who received fluoro-
quinolones for 1 to 4 days. The association was stronger for
those who received both ciprofloxacin and levofloxacin (n
= 124, AHR 4.61, 95% CI 1.16–18.41), intermediate for
those who received only ciprofloxacin (n = 1124, AHR
2.25, 95% CI 0.84–6.01), and absent for those who
received only levofloxacin (n = 363, AHR 1.10, 95% CI
0.13–9.35). None of the other classes of antimicrobial
drugs was associated with MRSA infection after adjust-
ment for confounders. According to multivariate analysis,
the following were no longer associated with MRSA infec-
tion: age, duration of hospital stay, a high Charlson score,
peripheral vascular disease or ischemic heart disease, ICU
stay, and tube feeding. No interaction was found. The small
number of outcomes precluded the identification of factors
protective against MRSA infection.
MSSA Infection
For MSSA infections (Table 3), the independent risk
factors were procedures and level of care (surgery, ICU
stay, enteral feeding) and some specific medical conditions
(diabetes mellitus, chronic renal failure, peripheral vascu-
lar disease). Univariate analyses showed several classes of
antimicrobial drugs to be associated with MSSA, but none
remained significant after adjustment for confounders. Sex
and immunosuppression were not associated with MSSA
infection (data not shown). No interaction was found.
Discussion
Interpretation of studies of the association of antimicro-
bial drug use and MRSA colonization or infection have
been plagued by methodologic problems such as case-con-
trol design (prone to biases in the selection of controls),
lack of adjustment for confounding variables, and the use
of cases of MSSA colonization or infection as controls (in
which instance an antimicrobial drug thought to be associ-
ated with MRSA can merely be protective against MSSA,
or vice-versa) (9,17,19,22). For these reasons, the associa-
tion between β-lactam antimicrobial drugs and MRSAcol-
onization or infection remains unclear, in contrast with the
more consistent relationship between these outcomes and
use of fluoroquinolones (9,17–19,22–24). We avoided
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sample large enough to allow adjustment for multiple con-
founding variables and in which patients with MRSA col-
onization or infection and MSSAinfection were compared
with those without such outcomes.
Fluoroquinolones were the only class of antimicrobial
drugs associated with MRSA colonization and infection.
AHRs were 2.57 and 2.49, respectively, presumably as a
result of their disruption of the patient’s complex microbi-
ological flora, the selective inhibition of susceptible
strains, and the increase in bacterial adhesion with surface
fibronectin binding proteins after exposure to
ciprofloxacin (25,26). Given the nearly identical AHRs for
the association between fluoroquinolones and MRSA col-
onization and infection, the latter was not likely due to
confounding by indication (e.g., clinicians who initiated
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tion ultimately found to be caused by MRSA).
Cotrimoxazole tended to confer protection against MRSA,
in agreement with a recent study showing that cotrimoxa-
zole prophylaxis reduces the incidence of community-
acquired MRSA among HIV-infected adults (27).
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MSSA, or MRSA.
The effect of fluoroquinolones and cotrimoxazole on
MRSA colonization and infection in patients was consis-
tent with their activity in vitro. Of the 23 clinical isolates
of MRSA from our patients, all were resistant to
ciprofloxacin, and all were sensitive to cotrimoxazole.
Among all clinical isolates of MRSA obtained during the
study period, 96% (346/361) were resistant to
ciprofloxacin and only 2% (8/361) were resistant to cotri-
moxazole. For clinical isolates of MSSA, 6% (87/1,538)
and 1% (10/1,538) were resistant to ciprofloxacin and cot-
rimoxazole, respectively.
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decrease the use of fluoroquinolones, which are given to
almost one fourth of all inpatients. In Quebec, among sub-
groups of patients who do not have preexisting renal dis-
ease and who receive antimicrobial drugs to treat
infections that are not life-threatening, the potential
adverse consequences of aminoglycoside nephrotoxicity
might be less than those of infections with MRSA and C.
difficile triggered by fluoroquinolones. A more selective
use of fluoroquinolones is possible, for instance, for
patients with urinary tract infections caused by pathogens
sensitive to cotrimoxazole or for patients who have
intraabdominal infections for whom β-lactam/β-lactamase
inhibitors might be considered. In contrast with its effect
on MRSA, use of antimicrobial drugs had little effect on
the risk for MSSA nosocomial infections. The risk factors
identified were those reported in the literature (1,12) and
offer little opportunity for prevention.
The association between peptic ulcer disease and both
MRSAcolonization and infection is intriguing but needs to
be interpreted with caution, given that 19 specific medical
conditions were tested. H2-blocker drugs were also associ-
ated with MRSA colonization, according to univariate
analysis, and had borderline significance according to mul-
tivariate analysis. Whether drugs that change gastric pH
might alter the microflora of the stomach and feces in a
way that facilitates MRSA colonization deserves further
study (28,29).
The major limitations of our study lie in its observation-
al nature. Patients not hospitalized during the previous
year were not screened for MRSAat the time of admission.
We considered such patients to be noncolonized initially,
and misclassification was unlikely, given the rarity of truly
community-acquired MRSA in our region. Subsequent
swabs to detect MRSA colonization were obtained from a
selected subsample of patients, who might have differed
from those not tested for characteristics related to the out-
come. The surveillance system selected patients at some-
what higher risk for MRSA colonization or infection, if
only because they were hospitalized longer. Whether our
findings can be extrapolated to low-risk patients is
unknown. The study was conducted in a hospital with
≈16% prevalence of methicillin resistance among isolates
of S. aureus, which limited the number of outcomes, espe-
cially for MRSA infection.
In conclusion, in a tertiary-care hospital with an inter-
mediate level of MRSAprevalence, fluoroquinolones were
the only antimicrobial drugs associated with MRSA colo-
nization and infection and, in conjunction with infection
control measures, represented the pharmacologic risk fac-
tor most amenable to correction. Before the C. difficile epi-
demic in hospitals of Quebec, the use of fluoroquinolones
had been very high, as in the United States (30). The risk
of inducing MRSA and CDAD should be taken into con-
sideration when selecting antimicrobial drugs to treat com-
mon infections.
Dr LeBlanc is a fellow in infectious diseases and clinical
microbiology at the University of Sherbrooke, Canada. Her
research interests include methicillin-resistant Staphylococcus
aureus.
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